{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:34:26Z","timestamp":1764599666717,"version":"3.46.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.acuroe.2025.501838","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:48:13Z","timestamp":1757774893000},"page":"501838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world data from a single-center cohort of patients with metastatic hormone-sensitive prostate cancer in Spain: Analysis of response, progression, and quality of life"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1383-1705","authenticated-orcid":false,"given":"J.","family":"Garc\u00eda Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"L\u00f3pez Tello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gonz\u00e1lez Ruiz de le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sacrist\u00e1n Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hevia Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Fuentes Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"P\u00e9rez Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Fern\u00e1ndez G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2025.501838_bib0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2024.07.013","article-title":"Systemic treatments for metastatic prostate cancer in 2024","volume":"10","author":"Gizzi","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.acuroe.2025.501838_bib0015","first-page":"562","article-title":"Factores relacionados con la resistencia a la castraci\u00f3n precoz en el c\u00e1ncer de pr\u00f3stata metast\u00e1sico. Resultados del Registro nacional de c\u00e1ncer de pr\u00f3stata en Espa\u00f1a","volume":"43","author":"Lloret-Dur\u00e1","year":"2019","journal-title":"AUE"},{"key":"10.1016\/j.acuroe.2025.501838_bib0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2025.501838_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2025.501838_bib0030","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2025.501838_bib0035","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103736","article-title":"Androgen receptor pathway inhibitors and drug\u2013drug interactions in prostate cancer","volume":"9","author":"Bolek","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.acuroe.2025.501838_bib0045","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41391-024-00816-0","article-title":"Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer","volume":"27","author":"George","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.acuroe.2025.501838_bib0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0055","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"10","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0060","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"20","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0065","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.65","article-title":"Survival outcomes of APA as a starting treatment: impact in real-world patients with mCSPC (OASIS)","volume":"42","author":"Maughan","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.acuroe.2025.501838_bib0075","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1080\/14656566.2018.1527312","article-title":"Advancing therapies in metastatic castration-resistant prostate cancer","volume":"19","author":"Baciarello","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.acuroe.2025.501838_bib0080","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1093\/oncolo\/oyad046","article-title":"Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer: results from an international study","volume":"7","author":"Barata","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.acuroe.2025.501838_bib0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12894-022-00979-9","article-title":"Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan","volume":"11","author":"Leith","year":"2022","journal-title":"BMC Urol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0090","article-title":"Comprehensive analysis of metastatic prostate cancer: real-world data from the Middle East","volume":"10","author":"Ramiz Abu-Hijlih Salah","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.10.024","article-title":"Leading from the front: real-world treatment of metastatic hormone-sensitive prostate cancer in the Northwest of England","volume":"38","author":"Singh","year":"2025","journal-title":"Clin Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.annonc.2023.09.2746","article-title":"1796P Real-world analysis of metastatic hormone-sensitive prostate cancer: are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer","volume":"34 Suppl 2","author":"G\u00f3mez Rivas","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0105","unstructured":"Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023. JCO Oncol Pract 0, OP-24-00690."},{"key":"10.1016\/j.acuroe.2025.501838_bib0110","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.3390\/cancers15184589","article-title":"Predictors of PSMA PET positivity: analysis in a selected cohort of biochemical recurrence prostate cancer patients after radical prostatectomy","volume":"15","author":"Mapelli","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.acuroe.2025.501838_bib0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41391-022-00544-3","article-title":"The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis","volume":"26","author":"Pozdnyakov","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.acuroe.2025.501838_bib0120","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.acuroe.2025.501838_bib0125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e17081","article-title":"Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume","volume":"41","author":"Freedland","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.acuroe.2025.501838_bib0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.prnil.2023.10.003","article-title":"Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: an observational, retrospective, and multicentre study","volume":"12","author":"L\u00f3pez-Abad","year":"2024","journal-title":"Prostate Int"},{"key":"10.1016\/j.acuroe.2025.501838_bib0135","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"1","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0140","article-title":"Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients","volume":"49","author":"Hassi Roman","year":"2025","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"10.1016\/j.acuroe.2025.501838_bib0145","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2025.501838_bib0150","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.urolonc.2018.12.020","article-title":"Depression and prostate cancer: a focused review for the clinician","volume":"37","author":"Fervaha","year":"2019","journal-title":"Urol Oncol"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625001787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625001787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:30:45Z","timestamp":1764599445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578625001787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2173578625001787"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501838","relation":{},"ISSN":["2173-5786"],"issn-type":[{"type":"print","value":"2173-5786"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data from a single-center cohort of patients with metastatic hormone-sensitive prostate cancer in Spain: Analysis of response, progression, and quality of life","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501838","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2025.501838","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501838"}}